ESR1 and breast cancer: For HER+ and ER−/HER2− recurrent breast cancers, TLSs were associated with longer PFS (p = 0.047), with the similar results for CD3+ cells (p = 0.023), CD38+ cells (p = 0.041), and CD68+ cells (p < 0.001) in TLSs.